Lymphoplasmacytic Lymphoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LYM012 MIFTS: 49	Lymphoplasmacytic Lymphoma Categories: Blood diseases, Cancer diseases, Immune diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Lymphoplasmacytic Lymphoma

MalaCards integrated aliases for Lymphoplasmacytic Lymphoma:

Name: Lymphoplasmacytic Lymphoma ¹¹ ¹⁴ ³⁶ ⁷⁵ ³³

Waldenström Macroglobulinaemia Without Mention of Remission ³³

Malignant Lymphoma - Lymphoplasmacytic ⁷¹

Waldenström Macroglobulinaemia ³³

Waldenstrom Macroglobulinemia ⁷¹

Idiopathic Macroglobulinaemia ³³

Primary Macroglobulinaemia ³³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Immune diseases Blood diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Mature B-cell neoplasms

Other specified mature B-cell neoplasms or lymphoma

Lymphoplasmacytic lymphoma

External Ids:

Disease Ontology ¹¹ DOID:0050747

ICD11 ³³ 2058944823

UMLS ⁷¹ C0024419 C0334633

Sources

Summaries for Lymphoplasmacytic Lymphoma

Disease Ontology: ¹¹ A B-cell lymphocytic neoplasm characterized by an uncontrolled increase of B-cells.

MalaCards based summary: Lymphoplasmacytic Lymphoma, also known as waldenström macroglobulinaemia without mention of remission, is related to macroglobulinemia and waldenstroem's macroglobulinemia. An important gene associated with Lymphoplasmacytic Lymphoma is PAX5 (Paired Box 5), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Cyclophosphamide and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone marrow and t cells, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia: ⁷⁵ Waldenström macroglobulinemia (/ˈvɑːldənstrɛm ˌmækroʊˌɡlɒbjələˈniːmiə/) is a type of cancer affecting... more...

Sources

Related Diseases for Lymphoplasmacytic Lymphoma

Diseases related to Lymphoplasmacytic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 341)

#	Related Disease	Score	Top Affiliating Genes
1	macroglobulinemia	31.4	SDC1 PAX5 MYD88 CXCR4 BTK BCL2
2	waldenstroem's macroglobulinemia	31.3	SDC1 PAX5 MYOM2 MYD88 MIR9-1 IGHV4-38-2
3	burkitt lymphoma	31.1	PAX5 MME CD19 BCL6 BCL2 B2M
4	lymphoma, hodgkin, classic	30.9	PAX5 MIR9-1 BCL6 BCL2
5	amyloidosis	30.8	MYOM2 MME CCND1 B2M
6	heavy chain disease	30.6	MYOM2 MYD88 IGHV4-38-2 CD79A
7	cryoglobulinemia	30.6	CD79A CD5 BCL2
8	pancytopenia	30.5	MME CD5 CD22 CD19
9	lymphoproliferative syndrome	30.5	CD5 BCL6 BCL2
10	lymphoma	30.5	PAX5 MYD88 CXCR4 CD5 CD38 CD19
11	immunoglobulin light chain amyloidosis	30.4	SDC1 MYOM2 IGHV4-38-2 CD38 B2M
12	hematologic cancer	30.4	PAX5 MIR9-1 CXCR4 BCL2
13	agammaglobulinemia	30.4	CXCR4 CD79B CD79A CD19 BTK
14	leukemia, chronic lymphocytic 2	30.4	CD5 CD38 BCL2
15	agammaglobulinemia, x-linked	30.3	CD79B CD79A CD19 BTK
16	mediastinal cancer	30.3	PAX5 CD79A CD5
17	gamma heavy chain disease	30.3	SDC1 PAX5 IGHV4-38-2 CD38 CD19
18	chromosome 13q14 deletion syndrome	30.2	IGHV4-38-2 CD5 CD38
19	anemia, autoimmune hemolytic	30.2	IGHV4-38-2 CD5 CD38 CD19 BTK
20	primary central nervous system lymphoma	30.2	PAX5 MYD88 BCL6
21	intravascular large b-cell lymphoma	30.2	BCL6 BCL2
22	prostate lymphoma	30.1	MME CD79A CD5 BCL6
23	deficiency anemia	30.0	MME CD5 CD38 CD19 B2M
24	bone lymphoma	30.0	PAX5 MME CD79A CD5 BCL6 BCL2
25	follicular lymphoma	30.0	PAX5 MME CXCR4 CD5 CCND1 BCL6
26	b-cell lymphoma	29.9	PAX5 MYD88 MME CXCR4 CD79B CD5
27	leukemia, chronic myeloid	29.9	MIR9-1 CD38 CD19 CCND1 BCL2
28	monoclonal gammopathy of uncertain significance	29.9	SDC1 MYOM2 MYD88 IGHV4-38-2 CD38 CD19
29	smoldering myeloma	29.8	SDC1 MYOM2 IGHV4-38-2 CD38 CD19 B2M
30	plasmacytoma	29.8	PAX5 CD79B CD79A CD5 CD38 CCND1
31	nodal marginal zone lymphoma	29.7	MME IGHV4-38-2 CD79A CD5 BCL6 BCL2
32	gastric lymphoma	29.7	MME IGHV4-38-2 CD79A CD5 BCL6 BCL2
33	plasma cell leukemia	29.7	SDC1 MYOM2 IGHV4-38-2 CD38 CCND1 B2M
34	plasma cell neoplasm	29.6	SDC1 PAX5 MYOM2 MYD88 IGHV4-38-2 CD79A
35	lymphatic system disease	29.5	MME MIR9-1 IGHV4-38-2 CD5 CD19 BCL6
36	diffuse large b-cell lymphoma	29.5	PAX5 MYD88 MME MIR9-1 IGHV4-38-2 CD79B
37	gastrointestinal lymphoma	29.5	MME IGHV4-38-2 CD79A CD5 CCND1 BCL6
38	composite lymphoma	29.4	PAX5 MME IGHV4-38-2 CD79A CD5 CD22
39	richter's syndrome	29.4	PAX5 IGHV4-38-2 CD79B CD5 CD38 CD22
40	splenic marginal zone lymphoma	29.3	PAX5 MYD88 MME IGHV4-38-2 CD79B CD79A
41	peripheral nervous system disease	29.2	MYOM2 MME MIR9-1 CXCR4 CD19 CCND1
42	marginal zone b-cell lymphoma	29.1	SDC1 PAX5 MYD88 MME IGHV4-38-2 CD79B
43	myeloma, multiple	29.0	SDC1 PAX5 MYOM2 MYD88 MIR9-1 CXCR4
44	chronic lymphocytic leukemia/small lymphocytic lymphoma	28.9	PAX5 MME IGHV4-38-2 CD79B CD79A CD5
45	leukemia, acute lymphoblastic	28.8	PAX5 MME MIR9-1 IGHV4-38-2 CXCR4 CD5
46	lymphoma, mucosa-associated lymphoid type	28.6	SDC1 PAX5 MYD88 MME IGHV4-38-2 CD79B
47	leukemia, chronic lymphocytic	28.4	SDC1 PAX5 MYD88 MME MIR9-1 IGHV4-38-2
48	mature b-cell neoplasm	28.3	SDC1 PAX5 MYOM2 MME MIR9-1 IGHV4-38-2
49	leukemia, acute myeloid	28.2	SDC1 PAX5 MME MIR9-1 IGHV4-38-2 CXCR4
50	lymphoma, non-hodgkin, familial	28.2	SDC1 PAX5 MYD88 MME MIR9-1 IGHV4-38-2

Graphical network of the top 20 diseases related to Lymphoplasmacytic Lymphoma:

Sources

Symptoms & Phenotypes for Lymphoplasmacytic Lymphoma

MGI Mouse Phenotypes related to Lymphoplasmacytic Lymphoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.17	B2M BCL2 BCL6 BTK CARD11 CCND1
2	cellular	MP:0005384	10.13	B2M BCL2 BCL6 BTK CARD11 CCND1
3	immune system	MP:0005387	10.09	B2M BCL2 BCL6 BTK CARD11 CCND1
4	neoplasm	MP:0002006	10.07	B2M BCL2 BTK CCND1 CD19 CD79A
5	hematopoietic system	MP:0005397	9.86	B2M BCL2 BCL6 BTK CARD11 CCND1
6	integument	MP:0010771	9.44	B2M BCL2 BCL6 BTK CARD11 CCND1

Sources

Drugs & Therapeutics for Lymphoplasmacytic Lymphoma

Drugs for Lymphoplasmacytic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cyclophosphamide

Approved, Investigational

Phase 4

50-18-0, 6055-19-2

2907

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

3003 5743

Bortezomib

Approved, Investigational

Phase 4

179324-69-7

387447 93860

Thalidomide

Approved, Investigational, Withdrawn

Phase 4

50-35-1

5426

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Etoposide

Approved

Phase 4

33419-42-0

36462

Cytarabine

Approved, Investigational

Phase 4

147-94-4

6253

Anti-Bacterial Agents

Phase 4

Anti-Infective Agents

Phase 4

Immunosuppressive Agents

Phase 4

Angiogenesis Inhibitors

Phase 4

Etoposide phosphate

Phase 4

16760419

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Chlorambucil

Approved

Phase 3

305-03-3

2708

Sirolimus

Approved, Investigational

Phase 3

53123-88-9

5284616 6436030

Azacitidine

Approved, Investigational

Phase 2, Phase 3

320-67-2

9444

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 3

133585-56-5, 60-18-4, 556-02-5

1153 6057

Cortisone

Experimental

Phase 2, Phase 3

53-06-5

222786

Cyclosporins

Phase 3

Antifungal Agents

Phase 3

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Hormones

Phase 3

Hormone Antagonists

Phase 3

Antiemetics

Phase 3

glucocorticoids

Phase 3

Anti-Inflammatory Agents

Phase 3

Gastrointestinal Agents

Phase 3

HIV Protease Inhibitors

Phase 3

protease inhibitors

Phase 3

BB 1101

Phase 3

Cc-486

Phase 2, Phase 3

Belimumab

Approved

Phase 2

356547-88-1

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Picropodophyllin

Approved, Investigational

Phase 2

518-28-5, 477-47-4

10607 72435

Ichthammol

Approved

Phase 1, Phase 2

8029-68-3

Vorinostat

Approved, Investigational

Phase 1, Phase 2

149647-78-9

5311

Vidarabine

Approved, Investigational

Phase 2

24356-66-9

21704

Erythromycin

Approved, Investigational, Vet_approved

Phase 2

114-07-8

12560

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Pentostatin

Approved, Investigational

Phase 2

53910-25-1

439693

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Panobinostat

Approved, Investigational

Phase 2

404950-80-7

6918837

Atorvastatin

Approved

Phase 2

134523-00-5

60823

Methotrexate

Approved

Phase 2

1959-05-2, 59-05-2

4112 126941

Iron

Approved

Phase 2

7439-89-6

29936

Deferasirox

Approved, Investigational

Phase 2

201530-41-8

214348 5493381

Interventional clinical trials:

(show top 50) (show all 330)

#	Name	Status	NCT ID	Phase	Drugs
1	Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China	Unknown status	NCT02844361	Phase 4
2	The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China	Unknown status	NCT02844322	Phase 4	Bortezomib;Rituximab
3	The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China	Unknown status	NCT02844309	Phase 4	Thalidomide
4	A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia	Active, not recruiting	NCT04042376	Phase 4	Ibrutinib
5	Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers	Unknown status	NCT02991638	Phase 3	Ibrutinib
6	Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma	Completed	NCT00566332	Phase 3	Chlorambucil;Fludarabine
7	First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG.	Completed	NCT00801281	Phase 3	Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
8	A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies	Completed	NCT00075478	Phase 3	Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
9	A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial	Completed	NCT01231412	Phase 3	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
10	A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)	Completed	NCT03053440	Phase 3	BGB-3111;Ibrutinib
11	A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes	Completed	NCT00608374	Phase 3	chlorambucil;fludarabine phosphate
12	iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia	Completed	NCT02165397	Phase 3	Ibrutinib;Placebo;Rituximab
13	Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib Alone in Waldenström's Macroglobulinemia (CZAR-1)	Recruiting	NCT04263480	Phase 3	Carfilzomib + Ibrutinib;Ibrutinib
14	Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia	Recruiting	NCT04061512	Phase 2, Phase 3	Dexamethasone, cyclophosphamide, rituximab;Rituximab, ibrutinib
15	Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia	Active, not recruiting	NCT01788020	Phase 3	Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
16	A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study	Enrolling by invitation	NCT01804686	Phase 3	Ibrutinib
17	A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements	Suspended	NCT04799275	Phase 2, Phase 3	Cyclophosphamide;Doxorubicin Hydrochloride;Oral Azacitidine;Prednisone;Vincristine Sulfate
18	A Phase 2 Study to Evaluate the Efficacy of Bortezomib in Patients With De-novo Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma	Unknown status	NCT03335098	Phase 2	Bortezomib
19	A Multicenter, Single-arm, Phase II Study to Evaluate a Safety and Efficacy of Obinutuzumab Induction Followed by 2 Years of Maintenance in Patients With Relapsed/Refractory Waldenström Macroglobulinemia.	Unknown status	NCT03679455	Phase 2	Obinutuzumab 25 MG/ML
20	Velcade/Dexamethasone/Cyclophosphamide(PCD) Versus Rituximab /Dexamethasone/Cyclophosphamide(RCD) for the Treatment of Patients With Waldenstrom's Macroglobulinemia	Unknown status	NCT02971982	Phase 1, Phase 2	rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide
21	Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia	Unknown status	NCT02981745	Phase 1, Phase 2	CT-1530
22	Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia	Unknown status	NCT00041379	Phase 1, Phase 2	beta alethine
23	A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia	Unknown status	NCT01142011	Phase 2	Belimumab
24	Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)	Completed	NCT00723099	Phase 2	Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
25	Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)	Completed	NCT00142181	Phase 2	Campath-1H
26	Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)	Completed	NCT00020800	Phase 2	fludarabine phosphate
27	A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies	Completed	NCT03010358	Phase 1, Phase 2	Entospletinib
28	Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia	Completed	NCT00142116	Phase 2	Thalidomide;Rituximab
29	Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas	Completed	NCT01076543	Phase 1, Phase 2	Lenalidomide;Temsirolimus
30	Phase II Study of Velcade in Waldenstrom's Macroglobulinemia	Completed	NCT00142129	Phase 2	Bortezomib (Velcade)
31	A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies	Completed	NCT01474681	Phase 1, Phase 2
32	A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphomas Refractory to Rituximab and Alkylating Agents	Completed	NCT01282424	Phase 2	Idelalisib
33	A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults	Completed	NCT01314014	Phase 2	Imexon
34	A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients With Relapsed Waldenstrom Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom Macroglobulinemia (Phase II)	Completed	NCT01381692	Phase 1, Phase 2	Bortezomib;Dexamethasone;Temsirolimus
35	A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia	Completed	NCT02302469	Phase 1, Phase 2	Revlimid
36	Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia	Completed	NCT02677324	Phase 2	ABT199
37	A Phase IIA Trial Testing the Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia	Completed	NCT00777738	Phase 2	BORTEZOMIB
38	A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial	Completed	NCT00789776	Phase 1, Phase 2	Cyclophosphamide;Fludarabine Phosphate;Mycophenolate Mofetil;Tacrolimus
39	A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE), and Dexamethasone (R-CYBOR-D) in Relapsed Low Grade and Mantle Cell Lymphoma	Completed	NCT00711828	Phase 2	Bortezomib;Cyclophosphamide;Dexamethasone
40	A Phase I/II Trial of CpG 7909, Rituximab Immunotherapy, and Y-90 Zevalin Radioimmunotherapy for Patients With Previously Treated CD20+ Non-Hodgkin Lymphoma	Completed	NCT00438880	Phase 1, Phase 2	Agatolimod Sodium
41	Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	Completed	NCT01008462	Phase 2	Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
42	A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma	Completed	NCT03364231	Phase 2	Umbralisib
43	Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies	Completed	NCT01093586	Phase 2	busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
44	A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial	Completed	NCT00105001	Phase 2	Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
45	UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia	Completed	NCT00083707	Phase 2	Thalidomide
46	A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia	Completed	NCT01109069	Phase 2	PCI-32765
47	Rituximab and Dexamethasone in CD20 Positive Low Grade and Follicular Non-Hodgkin's Lymphoma	Completed	NCT00244855	Phase 2	dexamethasone
48	A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy	Completed	NCT01075321	Phase 1, Phase 2	everolimus;lenalidomide
49	Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial	Completed	NCT00096161	Phase 2	Cyclosporine;Mycophenolate Mofetil;Pentostatin
50	A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies	Completed	NCT00072514	Phase 2	gemcitabine hydrochloride;carboplatin;dexamethasone

Search NIH Clinical Center for Lymphoplasmacytic Lymphoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Chlorambucil

Cyclophosphamide

Ibrutinib

Thalidomide

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Lymphoplasmacytic Lymphoma cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Lymphoplasmacytic Lymphoma:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies

Embryonic/Adult Cultured Cells Related to Lymphoplasmacytic Lymphoma:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells

Sources

Genetic Tests for Lymphoplasmacytic Lymphoma

Sources

Anatomical Context for Lymphoplasmacytic Lymphoma

Organs/tissues related to Lymphoplasmacytic Lymphoma:

MalaCards : B Cells, Bone Marrow, T Cells, Myeloid, Lymph Node, Liver, Bone

Sources

Publications for Lymphoplasmacytic Lymphoma

Articles related to Lymphoplasmacytic Lymphoma:

(show top 50) (show all 892)

#	Title	Authors	PMID	Year
1	Diagnosing Multiple Myeloma and Related Disorders. ⁶²	Moore AR	36270842	2023
2	A fatal case of a CD5-positive lymphoplasmacytic lymphoma with associated AL-type amyloidosis. ⁶²	Marchand A...Wang HY	35596646	2022
3	Bing-Neel Syndrome Successfully Treated with Tirabrutinib. ⁶²	Oyama T...Kurokawa M	35569989	2022
4	Bortezomib-based therapy is effective and well tolerated in frontline and multiply pre-treated Waldenström macroglobulinaemia including BTKi failures: A real-world analysis. ⁶²	Khwaja J...D'Sa S	36467794	2022
5	Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. ⁶²	Dogliotti I...Garcia-Sanz R	36435884	2022
6	Treatment of Patients with Waldenström Macroglobulinaemia: Clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. ⁶²	Talaulikar D...Medical and Scientific Advisory Group, Myeloma Australia	36441109	2022
7	Anemia - an initial manifestation of Bing-Neel syndrome: A case report. ⁶²	Yang X...Yan C	36401435	2022
8	Baseline 18 F-FDG PET/CT May Portend the Prognosis of Patients With Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma After First-Line Treatment. ⁶²	Pan Q...Li F	35961637	2022
9	Plasma cell neoplasms and related entities-evolution in diagnosis and classification. ⁶²	Fend F...Cook JR	36414803	2022
10	Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. ⁶²	Shadman M...Sharman JP	36400069	2022
11	Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: A diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis. ⁶²	Garcia-Abellas P...Garcia-Cosio M	36467836	2022
12	Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: a study of 29 cases including cases that can mimic plasma cell neoplasms. ⁶²	Qiu L...Lin P	36244464	2022
13	Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma. ⁶²	Baloda V...Bailey NG	36266677	2022
14	Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib. ⁶²	Yasuda H...Ando M	36247137	2022
15	Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia. ⁶²	Moreno DF...Fernandez de Larrea C	36210485	2022
16	Protein-losing enteropathy in association with gastrointestinal IgM deposition in Waldenström macroglobulinaemia. ⁶²	Liston K...McHugh J	35796502	2022
17	A Rare Case of Laryngeal Non-IgM Lymphoplasmacytic Lymphoma. ⁶²	Hong MK...Shiba TL	36159343	2022
18	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. ⁶²	Tun AM...Maurer MJ	35849723	2022
19	Overexpression of interleukin-20 correlates with favourable prognosis in diffuse large B-cell lymphoma. ⁶²	Lu YS...Chang KC	36175183	2022
20	Research progress on epigenetics of small B-cell lymphoma. ⁶²	Ruan X...Peng H	35334078	2022
21	Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma. ⁶²	Baloda V...Bailey NG	35932039	2022
22	The Role of [68Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review. ⁶²	Albano D...Treglia G	35954476	2022
23	Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study ⁶²	Kivrak H...Kuzu I	34619856	2022
24	Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib. ⁶²	Sekiguchi Y...Kobayashi H	35110483	2022
25	Cutaneous lymphoplasmacytic lymphoma with MYD88 L265P mutation, bone marrow involvement, and paraproteinaemia. ⁶²	Bruehl FK...Habeeb O	34895930	2022
26	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. ⁶²	Sermer D...Castillo JJ	35339405	2022
27	New treatment strategies for Waldenström macroglobulinemia. ⁶²	Moreno DF...Castillo JJ	36125957	2022
28	Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia-A Multicenter Report by the Polish Lymphoma Research Group. ⁶²	Drozd-Sokolowska J...Basak G	35956064	2022
29	A Focus on Waldenström Macroglobulinemia and AL Amyloidosis. ⁶²	Lu R...Richards T	35937468	2022
30	Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM. ⁶²	Wang J...Yi S	35537114	2022
31	Primary radiation therapy in stage I/II indolent orbital lymphoma - a comprehensive retrospective recurrence and toxicity analysis. ⁶²	Eze C...Li M	35276022	2022
32	Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation. ⁶²	Righi S...Sabattini E	35339566	2022
33	Acute kidney injury due to direct infiltration by lymphoplasmacytic lymphoma secreting IgG paraproteins: A case report. ⁶²	Kim S...Park DJ	35713455	2022
34	Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation. ⁶²	DeRosa PA...Agarwal A	35877223	2022
35	Russell Body Esophagitis: A Possible Indication to Screen for Hematologic Malignancy. ⁶²	Garcia GE...Staffetti J	35770181	2022
36	Clinicoradiopathological correlation of symptomatic focal bone marrow lesions in Waldenström Macroglobulinaemia. ⁶²	Arulogun SO...D'Sa SP	35067139	2022
37	A challenging case of lymphoproliferative disease in a cat. ⁶²	Palic J...Turba ME	35181934	2022
38	Response to vaccination against SARS-CoV-2 in 168 patients with Waldenström macroglobulinaemia: A French Innovative Leukaemia Organization study. ⁶²	Tomowiak C...FILO (French Innovative Leukaemia Organization) group	35029297	2022
39	Central nervous system manifestations of systemic haematological malignancies and key differentials. ⁶²	Lasocki A...Seymour JF	35164931	2022
40	A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform. ⁶²	Zhang W...Xiao M	34802044	2022
41	A rare case of type II cryoglobulinemic vasculitis with renal and pulmonary involvement in a patient with underlying lymphoplasmacytic lymphoma. ⁶²	Edmonds N...Flowers RH	35383893	2022
42	Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing-Neel syndrome. ⁶²	Saburi M...Ohtsuka E	34699012	2022
43	Concomitant lymphoplasmacytic lymphoma, multiple myeloma, and amyloidosis: A diagnostic and therapeutic challenge. ⁶²	Ceballos C...Mateos MC	35474975	2022
44	Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance. ⁶²	Drandi D...Ferrero S	35454017	2022
45	Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. ⁶²	Pratt G...Owen R	35020191	2022
46	Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas. ⁶²	Minson A...Seymour JF	35267584	2022
47	Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. ⁶²	Egyed M...Illes A	35139644	2022
48	Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study. ⁶²	Brandefors L...Kimby E	34959252	2022
49	Reversible Systolic Heart Failure in a Patient on Ibrutinib Chemotherapy. ⁶²	Khaja M...Haider A	35449638	2022
50	Constrictive Pericarditis Revealing Rare Case of ALH Amyloidosis With Underlying Lymphoplasmacytic Lymphoma (Waldenstrom Macroglobulinemia). ⁶²	Ho VV...Witteles RM	35257101	2022

Sources

Genes for Lymphoplasmacytic Lymphoma

Genes related to Lymphoplasmacytic Lymphoma (0 elite genes):

(show all 27)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	PAX5	Paired Box 5	Protein Coding	22.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
2	BTK	Bruton Tyrosine Kinase	Protein Coding	8.05	DISEASES inferred ¹⁴
3	MYD88	MYD88 Innate Immune Signal Transduction Adaptor	Protein Coding	8.05	DISEASES inferred ¹⁴
4	CD5	CD5 Molecule	Protein Coding	7.52	DISEASES inferred ¹⁴
5	IGHV4-38-2	Immunoglobulin Heavy Variable 4-38-2	Protein Coding	7.34	DISEASES inferred ¹⁴
6	SDC1	Syndecan 1	Protein Coding	7.21	DISEASES inferred ¹⁴
7	MYOM2	Myomesin 2	Protein Coding	7.1	DISEASES inferred ¹⁴
8	CD19	CD19 Molecule	Protein Coding	7.1	DISEASES inferred ¹⁴
9	CD79B	CD79b Molecule	Protein Coding	7.04	DISEASES inferred ¹⁴
10	MME	Membrane Metalloendopeptidase	Protein Coding	7.04	DISEASES inferred ¹⁴
11	CD79A	CD79a Molecule	Protein Coding	6.82	DISEASES inferred ¹⁴
12	MIR9-1	MicroRNA 9-1	RNA Gene	6.81	DISEASES inferred ¹⁴ ¹⁴
13	CD38	CD38 Molecule	Protein Coding	6.78	DISEASES inferred ¹⁴
14	CXCR4	C-X-C Motif Chemokine Receptor 4	Protein Coding	6.75	DISEASES inferred ¹⁴
15	CD22	CD22 Molecule	Protein Coding	6.67	DISEASES inferred ¹⁴
16	BCL6	BCL6 Transcription Repressor	Protein Coding	6.55	DISEASES inferred ¹⁴
17	B2M	Beta-2-Microglobulin	Protein Coding	6.43	DISEASES inferred ¹⁴
18	BCL2	BCL2 Apoptosis Regulator	Protein Coding	6.35	DISEASES inferred ¹⁴
19	CARD11	Caspase Recruitment Domain Family Member 11	Protein Coding	6.34	DISEASES inferred ¹⁴
20	CCND1	Cyclin D1	Protein Coding	6.18	DISEASES inferred ¹⁴
21	IRAK4	Interleukin 1 Receptor Associated Kinase 4	Protein Coding	6.12	DISEASES inferred ¹⁴
22	MAG	Myelin Associated Glycoprotein	Protein Coding	6.03	DISEASES inferred ¹⁴
23	PLCG2	Phospholipase C Gamma 2	Protein Coding	6.03	DISEASES inferred ¹⁴
24	IRAK1	Interleukin 1 Receptor Associated Kinase 1	Protein Coding	6.03	DISEASES inferred ¹⁴
25	SPN	Sialophorin	Protein Coding	5.98	DISEASES inferred ¹⁴
26	IRF4	Interferon Regulatory Factor 4	Protein Coding	5.92	DISEASES inferred ¹⁴
27	CD27	CD27 Molecule	Protein Coding	5.92	DISEASES inferred ¹⁴

Sources

Variations for Lymphoplasmacytic Lymphoma

Sources

Expression for Lymphoplasmacytic Lymphoma

Search GEO for disease gene expression data for Lymphoplasmacytic Lymphoma.

Sources

Pathways for Lymphoplasmacytic Lymphoma

Pathways related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

(show all 20)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.77	B2M BCL2 BCL6 BTK CARD11 CCND1
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.62	B2M BTK CCND1 CD19 CD79A CD79B
3	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.33	MYD88 CD79B CD79A CD19 CCND1 BTK
4	Class I MHC mediated antigen processing and presentation ⁶⁶ Show member pathways Adaptive Immune System ⁶⁶ Antigen processing: Ubiquitination and Proteasome degradation ⁶⁶ Neddylation ⁶⁶	13.27	MYD88 CD79B CD79A CD22 CD19 CARD11
5	Immune response Fc epsilon RI pathway ²² Show member pathways Fc-epsilon receptor I signaling in mast cells ⁶¹ Immune response BCR pathway ²²	12.18	CD79B CD79A CD22 CD19 BTK BCL6
6	B Cell Receptor Signaling Pathway ⁶⁷ Show member pathways T Cell Receptor Signaling Pathway ⁶⁷	12.08	CD22 CD19 BTK BCL6
7	NF-kappaB Signaling ³	11.84	PAX5 MYD88 CXCR4 CD79A CD38 CD19
8	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.79	CCND1 BCL6 BCL2
9	DNA damage response (only ATM dependent) ⁷⁴	11.76	CCND1 BCL6 BCL2
10	Notch Signaling Pathways ⁶⁵	11.74	CCND1 BCL6 BCL2
11	Potential therapeutics for SARS ⁶⁶	11.73	CD79B CD79A BTK
12	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.7	SDC1 CD79A CD19
13	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.62	SDC1 MME CD79B CD79A CD5 CD38
14	C-MYB transcription factor network ⁶¹	11.6	PAX5 CCND1 BCL2
15	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.59	PAX5 CXCR4 CD79A CD22 CD19 BCL6
16	Burn wound healing ⁷⁴	11.56	MYD88 CXCR4 BCL2
17	Acute viral myocarditis ⁷⁴	11.55	CXCR4 CCND1 BCL2
18	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.52	MME CD38 CD19
19	BCR signaling pathway ⁶¹	11.51	BCL6 BTK CARD11 CD19 CD22 CD79A
20	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers ⁶⁶ Show member pathways B-Cell Receptor Complex ⁶⁴ CD22 mediated BCR regulation ⁶⁶	11.31	CD79B CD79A CD22 CD19 BTK

Sources

GO Terms for Lymphoplasmacytic Lymphoma

Cellular components related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane raft	GO:0045121	9.65	MME CD79A CD19 CARD11 BTK
2	external side of plasma membrane	GO:0009897	9.55	SDC1 IGHV4-38-2 CXCR4 CD79B CD79A CD5
3	B cell receptor complex	GO:0019815	9.46	CD79B CD79A

Biological processes related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	I-kappaB kinase/NF-kappaB signaling	GO:0007249	10	MYD88 CARD11 BTK
2	B cell proliferation	GO:0042100	9.96	CD79A CD38 CARD11 BCL6 BCL2
3	immune system process	GO:0002376	9.92	B2M BCL6 BTK CARD11 CD19 CD79A
4	response to glucocorticoid	GO:0051384	9.91	SDC1 CCND1 BCL2
5	B cell activation	GO:0042113	9.91	CD79A CD22 BTK
6	regulation of immune response	GO:0050776	9.88	CD22 CARD11 BCL6
7	positive regulation of B cell proliferation	GO:0030890	9.85	BCL2 BCL6 BTK CARD11 CD38
8	response to organic cyclic compound	GO:0014070	9.8	MYD88 CXCR4 CCND1 BCL2
9	response to organic substance	GO:0010033	9.67	SDC1 CCND1 BTK
10	B cell differentiation	GO:0030183	9.65	PAX5 CD79B CD79A CARD11 BCL6 BCL2
11	regulation of programmed cell death	GO:0043067	9.63	CXCR4 BCL2
12	negative regulation of leukocyte proliferation	GO:0070664	9.54	BTK BCL6
13	B cell receptor signaling pathway	GO:0050853	9.44	IGHV4-38-2 CD79B CD79A CD38 CD19 BTK